MARLBOROUGH, Mass., April 19, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that in a new study,
The multi-center, IRB-approved retrospective case control study surveyed 189 pre-menopausal women who underwent endometrial ablation in accordance with FDA-approved use of either the NovaSure or Minerva device (97 NovaSure and 92 Minerva).1 The primary efficacy outcome was the percentage of patients experiencing amenorrhea post-ablation; the mean follow-up was 11.3 months (range 137 – 532 days). Secondary efficacy outcomes were change in abnormal uterine bleeding (AUB) symptom severity from baseline, the percentage of patients requiring secondary intervention (medical or surgical) for refractory AUB, and patient satisfaction level.1 The primary safety-related outcome was the incidence of perioperative adverse events, which included, among others, pain, fever, nausea, vomiting, vaginal bleeding, and vaginosis.1
NovaSure Pivotal Study Information
The pivotal study supporting FDA approval of the NovaSure system on September 28, 2001 was a randomized, prospective, multi-center clinical study, in which the NovaSure system was compared to a control arm of wire loop resection plus rollerball endometrial ablation (hysteroscopic endometrial ablation). A total of 265 patients were enrolled in the study, with 175 being randomized into the NovaSure study arm. The NovaSure study arm reported 1-year success rates of 77.7% and 1-year amenorrhea rates of 36%. Patient success was based on a reduction in a menstrual diary score from ? 150 pre-treatment to ? 75 at one-year post-treatment, using a validated menstrual dairy scoring system developed by Higham.11 Patient satisfaction was assessed by administering Quality of Life (SF-12 Questionnaire) and Menstrual Impact questionnaires prior to treatment and at 3, 6 and 12 months post-treatment, with 92.8% of NovaSure patients reporting being satisfied or very satisfied with the procedure after 1 year.
For more information on the NovaSure procedure, visit www.NovaSure.com, and for its full product labeling, visit www.NovaSure.com/hcp/resources/ifus.
About Abnormal Uterine Bleeding (AUB)
Abnormal uterine bleeding (AUB), or menorrhagia, affects up to 30% of premenopausal women,2 and negatively impacts quality of life (QoL).3 Medical treatment of AUB is often effective, but associated costs and potential adverse effects (AEs) of long-term treatments restrict patient adherence.4 Hysterectomy, while a decisive treatment for AUB if other treatments fail, is an aggressive approach that carries risk of serious short-term and long-term AEs, as well as an increased risk of cardiovascular disease.5?7 Endometrial ablation is an effective, less-invasive surgical option for treating AUB, using either resectoscopy or newer second-generation techniques that deliver high-dose energy to uniformly destroy the entire uterine lining.8?10
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, NovaSure, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.
Important Safety Information
NovaSure® endometrial ablation is for premenopausal women with heavy periods due to benign causes who are finished childbearing. Pregnancy following the NovaSure procedure can be dangerous. The NovaSure procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. NovaSure endometrial ablation is not a sterilization procedure. Rare but serious risks include, but are not limited to, thermal injury, perforation and infection. Temporary side effects may include cramping, nausea, vomiting, discharge and spotting. Inform patients to contact you if they experience a possible side effect related to use of this product. For detailed benefit and risk information, please consult the IFU.
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to email@example.com.
Media Contact: Jane Mazur508.263.8764 (direct) 585.355.5978 (mobile) firstname.lastname@example.org
Investor Contact:Michael Watts858.email@example.com
View original content:http://www.prnewswire.com/news-releases/women-treated-with-hologics-novasure-endometrial-ablation-system-in-new-study-reported-higher-amenorrhea-rates-than-those-treated-with-minerva-300633364.html
SOURCE Hologic, Inc.
Subscribe to our Free Newsletters!